Novel CD2-targeted bispecific antibody enhances T cell engagers for solid tumors
A novel CD2-targeted bispecific antibody combined with CD3 T cell engager shows improved efficacy and reduced toxicity in solid tumors.
Asset / Drug
Drug and asset intelligence for tarlatamab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.